Cargando…

Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus

OBJECTIVE: Hydroxychloroquine (HCQ) is a mainstay of therapy in the treatment of SLE. The effect of HCQ on platelets and vascular health is uncertain. We investigated the relationship between HCQ use and dose with platelet activity, platelet transcriptomics and vascular health in patients with SLE....

Descripción completa

Detalles Bibliográficos
Autores principales:	Cornwell, MacIntosh Grant, Luttrell-Williams, Elliot S, Golpanian, Michael, El Bannoudi, Hanane, Myndzar, Khrystyna, Izmirly, Peter, Belmont, H Michael, Katz, Stuart, Smilowitz, Nathaniel R, Engel, Alexis, Clancy, Robert, Ruggles, Kelly, Buyon, Jill P, Berger, Jeffrey S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Biomarker Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978255/ https://www.ncbi.nlm.nih.gov/pubmed/33737451 http://dx.doi.org/10.1136/lupus-2021-000475

Ejemplares similares

Modeling of clinical phenotypes in systemic lupus erythematosus based on the platelet transcriptome and FCGR2a genotype
por: Cornwell, MacIntosh G., et al.
Publicado: (2023)

Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)
por: Conklin, John, et al.
Publicado: (2022)

Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and Crithidia luciliae assay in a multiethnic racial cohort of patients with SLE
por: Zaminski, Devyn, et al.
Publicado: (2023)

Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study
por: Fernandez-Ruiz, Ruth, et al.
Publicado: (2020)

Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus
por: Fasano, Serena, et al.
Publicado: (2022)

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus
por: Buyon, Jill, et al.
Publicado: (2016)

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements
por: Putterman, Chaim, et al.
Publicado: (2014)

Platelet Activity and Cardiovascular Risk in CKD and Peripheral Artery Disease
por: Cofer, Lucas B., et al.
Publicado: (2022)

Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus
por: Raymond, Warren David, et al.
Publicado: (2021)

Risk factors, transcriptomics, and outcomes of myocardial injury following lower extremity revascularization
por: Smilowitz, Nathaniel R., et al.
Publicado: (2022)

Platelets amplify endotheliopathy in COVID-19
por: Barrett, Tessa J., et al.
Publicado: (2021)

Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2018)

Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus
por: Mackay, Meggan, et al.
Publicado: (2015)

Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children
por: Brunner, Hermine I, et al.
Publicado: (2014)

Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection
por: Mackay, Meggan, et al.
Publicado: (2016)

TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
por: Idborg, Helena, et al.
Publicado: (2018)

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
por: Northcott, Melissa, et al.
Publicado: (2022)

Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus
por: Sadras, Vignesh, et al.
Publicado: (2020)

Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus
por: Petri, Michelle A, et al.
Publicado: (2020)

Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus
por: Ruacho, Guillermo, et al.
Publicado: (2022)

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
por: Merrill, Joan T, et al.
Publicado: (2018)

Elevation of serum anti–glucose-regulated protein 78 antibodies in neuropsychiatric systemic lupus erythematosus
por: Matsueda, Yu, et al.
Publicado: (2018)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products
por: Wallace, Daniel J, et al.
Publicado: (2016)

Differential expression of antibodies to NMDA receptor in anti-NMDA receptor encephalitis and in neuropsychiatric systemic lupus erythematosus
por: Hirohata, Shunsei, et al.
Publicado: (2019)

RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin
por: Merola, Joseph F, et al.
Publicado: (2021)

Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up
por: Schoindre, Yoland, et al.
Publicado: (2014)

Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density
por: Shevchuk, Sergii, et al.
Publicado: (2023)

Potential Biomarker Identification by RNA-Seq Analysis in Antibiotic-Related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Pilot Study
por: Teo, Ying Xin, et al.
Publicado: (2022)

Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies
por: Brunekreef, Tammo, et al.
Publicado: (2021)

Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus
por: Anderson, Erik W, et al.
Publicado: (2021)

A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus
por: Alexander, Roberta Vezza, et al.
Publicado: (2021)

Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus
por: Nielsen, Christoffer T, et al.
Publicado: (2014)

Urinary miRNA Biomarkers of Drug-Induced Kidney Injury and Their Site Specificity Within the Nephron
por: Chorley, Brian N, et al.
Publicado: (2020)

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED‐HF study
por: Welsh, Paul, et al.
Publicado: (2017)

Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium
por: Bahls, Martin, et al.
Publicado: (2019)

Rapid aneurysm growth and rupture in systemic lupus erythematosus
por: Graffeo, Christopher S., et al.
Publicado: (2015)

Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients
por: Drechsler, Christiane, et al.
Publicado: (2011)

Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial
por: Maisel, Alan S., et al.
Publicado: (2011)

Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy
por: Tolosana, Jose María, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bhqb6rfldpfc1p42ufd456e2tn